T227. THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 REGULATES STRIATAL DOPAMINE RELEASE VIA AN ENDOCANNABINOID-DEPENDENT MECHANISM: IMPLICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA

BACKGROUND: Clinical and preclinical studies suggest that selective activators of the muscarinic M4 receptor have exciting potential as a novel approach for treatment of schizophrenia. M4 reduces striatal dopamine (DA) though release of endocannabinoids (eCB), providing a mechanism for local effects...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Schizophr Bull
Autors principals: Yohn, Samantha, Covey, Daniel, Foster, Daniel, Moehle, Mark, Galbraith, Jordan, Cheer, Joseph, Lindsley, Craig, Jeffrey Conn, P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887981/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sby016.503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars